Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T35420 |
(S)-p38 MAPK Inhibitor III
(S)-p38 MAPK Inhibitor III |
||
(S)-p38 MAPK inhibitor III is a methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro). It is cell-permeable, potently blocking the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively). | |||
T22115 |
SM-7368
|
NF-κB | NF-κB |
NF-κB Activation Inhibitor III 是一种NF-kB 抑制剂,抑制 TNF-α 诱导的MMP-9上调,靶向抑制下游的MAPK p38,可用于靶向 TNF-α 介导的肿瘤侵袭和转移的化疗研究。 | |||
T68297 |
Dilmapimod tosylate
|
||
Dilmapimod tosylate is a potent p38 mitogen-activated protein kinase (MAPK) inhibitor. It was investigated for its anti-inflammatory effect in non-head injury trauma patients at risk for developing acute respiratory distress syndrome. IL-1β was identified as a gene regulated by dilmapimod that could influence c-reactive protein levels. Dilmapimod had been in phase III clinical trials by GlaxoSmithKline for the treatment of rheumatoid arthritis, neuropathic pain, coronary artery disease (CAD) and... |